REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material > Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.) Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.)Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.08/16/07 - 20070190049 - Use of a33 antigens and jam-it The present invention relates to compositions and methods of treating and diagnosing disorders characterized the by the presence of antigens associated with inflammatory diseases and/or cancer. ... 08/16/07 - 20070190048 - Method of inducing physiological process in a body cavity and a device for using it The invention also relates to a device for using said method comprising a hollow body (1) provided with a heat source on the inside as well as with a means (13, 27) of removal of said hollow body from the vaginal or rectal cavity and a means (6, 8, 10) ... 08/16/07 - 20070190047 - Formulations that inhibit protein aggregation Disclosed is a stable pharmaceutically acceptable formulation containing a pharmaceutically acceptable amount of a protein. Also disclosed are methods for preparing such formulations and methods for inhibiting protein aggregate formation induced by physical stresses associated with processing, manufacture, shipping, and storing protein formulations, particularly freeze/thaw stress. ... 08/16/07 - 20070190046 - Anti-abeta antibody This present invention provides a composition that is suitable for administration to a human subject comprising an anti-Aβ antibody that is free of Aβ peptide or that has acceptably low levels thereof, free of non-human Aβ peptide or that has acceptably low levels thereof, or having an undetectable concentration of ... 08/09/07 - 20070184049 - Antibody therapy for treatment of diseases associated with gluten intolerance The present invention includes a pharmaceutical compositions and methods for treating diseases associated with gluten intolerance in a patient, comprising: administering to the patient an effective amount of an antibody having specific activity against gluten or gluten-derived peptides. Such diseases include, for example, celiac disease and dermatitis herpetiformis. ... 08/09/07 - 20070184048 - Re-targeted toxin conjugates The present invention provides a method for designing a re-targeted toxin conjugate for use in treating a medical condition or disease. Also provided, is the use of said conjugates in the manufacture of a medicament for treating medical conditions or diseases. The conjugates include a Targeting Moiety, which directs the ... 07/19/07 - 20070166305 - Method of modulating the activity of functional immune molecules The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity. ... 07/19/07 - 20070166304 - Method of modulating the activity of functional immune molecules The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity. ... 07/19/07 - 20070166303 - Method of modulating the activity of functional immune molecules The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity. ... 07/19/07 - 20070166302 - Method of modulating the activity of functional immune molecules The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the liker an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity. ... 07/19/07 - 20070166301 - Method of modulating the activity of functional immune molecules The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity. ... 07/19/07 - 20070166300 - Method of modulating the activity of functional immune molecules The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity. ... 07/12/07 - 20070160598 - Binding polypeptides with diversified and consensus vh/vl hypervariable sequences The invention provides variant hypervariable regions comprising selected amino acid sequence diversity. Libraries comprising a plurality of these polypeptides are also provided. In addition, methods of and compositions for generating and using these polypeptides and libraries are provided. ... 07/12/07 - 20070160597 - Optimized fc variants and methods for their generation The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. ... 07/12/07 - 20070160596 - Proline rich acidic protein and uses thereof The present invention relates to isolated polynucleotide comprising a sequence selected from the group consisting of: (a) a polynucleotide comprising a sequence encoding the polypeptide SEQ ID NO:3 or a biologically active or immunogenic fragment thereof; (b) a polynucleotide comprising a sequence encoding the polypeptide SEQ ID NO:4 or a ... 07/05/07 - 20070154473 - Anti-cd19 antibodies with reduced immunogenicity Anti-CD19 B4 antibodies with modified variable regions are disclosed. The modified anti-CD19 variable region polypeptides have alterations to one or more framework regions or complementarity determining regions of the heavy chain variable region or light chain variable region, thereby to reduce a T-cell response. ... 07/05/07 - 20070154472 - Sulfotyrosine specific antibodies and uses therefor This application relates to sulfotyrosine specific antibodies that are capable of binding selectively to sulfated tyrosine (sulfotyrosine), as well as their production and use. In certain embodiments, the antibodies distinguish sulfated tyrosine containing proteins from phosphorylated tyrosine containing proteins. Methods to detect or quantitate the presence of sulfotyrosine and/or sulfotyrosine ... 07/05/07 - 20070154471 - Method for generating f(ab')2 antibody fragments Methods for generating F(ab′)2 fragments from antibodies using thermolysin as well as F(ab′)2 fragments and compositions comprising F(ab′)2 fragments generated by the method are described. ... 07/05/07 - 20070154470 - Holt's o(log n) method to search a massively poly-clonal collection of hybridomas to detect, select and isolate target-antigen-specific high-affinity monoclonal-antibody-generating hybridomas for the rapid development and manufacture of highly specific an This invention is an O(Log N) technique that searches a massively poly-clonal collection of hybridomas (or other monoclonal antibody generators) to detect, select and isolate target-antigen-specific high-affinity monoclonal-antibody-generating hybridomas (or other monoclonal antibody generators) for the rapid development and manufacture of highly specific and effectively targeted monoclonal antibodies. It expedites ... 07/05/07 - 20070154469 - Igm production by transformed cells and methods of quantifying said igm production IgM can be obtained in the form of a pentamer by placing the genes encoding the H, L, and J chains on the same vector to transform appropriate host cells. The gene encoding the J chain may be introduced by co-transfection. When no J chain is expressed, the IgM is ... 06/28/07 - 20070148168 - Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions The present invention relates to compositions and methods for prevention and treatment of diseases and conditions, including ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation and/or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against bioactive lipids ... 06/28/07 - 20070148167 - Non-immunostimulatory antibody and compositions containing the same The present invention relates to a non-immunostimulatory antibody which lacks antibody-dependent cell-mediated cytotoxicity, Fc gamma receptor binding and complement-mediated cytotoxicity. In some embodiments, the antibody contains a modified immunoglobulin G2 (IgG2) Fc region with at least one substitution in the B/C loop, FcRn binding domain, and the F/G loop. The ... 06/28/07 - 20070148166 - Scfvs in photosynthetic microbes Expression of functionally active recombinant single chain antibodies in prokaryotic and eukaryotic heterotrophic algae for pathogen treatment or control in aquaculture and agriculture applications is disclosed; and subsequent modification of the strains to generate transgenic algae propagated under defined conditions. ... 06/28/07 - 20070148165 - Recombinant antibody composition The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence ... 06/28/07 - 20070148164 - Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto The compositions and methods of the present invention are based, in part, on our discovery that an effector function mediated by an Fc-containing polypeptide can be altered by modifying one or more amino acid residues within the polypeptide (by, for example, electrostatic optimization). The polypeptides that can be generated according ... 06/21/07 - 20070141049 - Bivalent igy antibody constructs for diagnostic and therapeutic applications This invention relates to the field of recombinant antibody technology. It provides novel recombinant IgY antibody constructs for diagnostic and therapeutical applications. The bivalent antibody constructs display a heterotetrameric or homodimeric format stabilized by disulfide bonds. The constant heavy chain domains CH2-CH4 are partly or completely of avian origin, whereas ... 06/21/07 - 20070141048 - Method for linking sequences of interest Multiplex overlap-extension RT-PCR provides an efficient method of linking two or more nucleotide sequences encoding for domains or subunits of a heteromeric protein, in a single reaction. Especially, the linkage of variable region encoding sequences from e.g. immunoglobulins, T cell receptors or B cell receptors is eased with the method ... 06/14/07 - 20070134235 - Endothelialization of vascular surfaces Endothelialization of vascular surfaces. According to one aspect, the invention involves a technique for re-endothelializing an artery whose endothelial layer has been damaged by balloon angioplasty. The technique comprises, in one embodiment, introducing into the bloodstream of a patient, prior to performing the angioplasty, a quantity of a bispecific antibody, ... 06/14/07 - 20070134234 - Immunomodulatory compositions and uses therefor The poxvirus proteins designated A41L and 130L bind to three receptor-like protein tyrosine phosphatases (RPTP), leukocyte common antigen related protein (LAR), RPTP-δ, and RPTP-σ, that are present on the cell surface of immune cells. When a host is infected with the poxvirus, binding of A41L to cell surface proteins on ... 06/14/07 - 20070134233 - Compositions and methods relating to organ-, tissue-, and cell-specific antibodies Disclosed are methods for producing organ-, tissue-, or cell-specific antibodies, antibodies against developmentally regulated antigens, antibodies against disease-associated antigens, and antibodies against antigens that are modulated during a physiological response to an agent (e.g., in response to a drug). Also disclosed are methods for screening an agent for activity in ... 05/31/07 - 20070122403 - Molecules with extended half-lives, compositions and uses thereof The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant ... 05/31/07 - 20070122402 - Immunoglobulin preparations having increased stability The present invention relates to a protein preparation having increased stability, comprising a stabiliser selected from the group consisting of non-polar and basic amino acids and having a pH of 4.0 to 5.2. The invention further relates to a pharmaceutical composition and a method of stabilising protein preparations. ... 05/24/07 - 20070116700 - Reduced-viscosity concentrated protein formulations The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations. ... 05/17/07 - 20070110743 - Methods of protein production using anti-senescence compounds Methods of producing a protein in cell culture comprising an anti-senescence compound, such as the antioxidant carnosine, are provided. According to teachings of the present invention, cells grown in a cell culture medium comprising an anti-senescence compound exhibit increased viability and productivity. Furthermore, cell cultures grown in the presence of ... 05/10/07 - 20070104708 - Compositions, methods, and kits relating to resistin The invention relates to novel nucleic acids encoding a mammalian resistin gene, and proteins encoded thereby, whose expression is suppressed by the antidiabetic compounds thiazolidinediones. The invention further relates to methods of treating and detecting type 2 diabetes and Syndrome X comprising modulating or detecting resistin expression and/or production and ... 05/10/07 - 20070104707 - Methods of diagnosing and treating complications of pregnancy Disclosed herein are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using combinations of compounds that alter soluble endoglin and sF1t-1 expression levels or biological activity. Also disclosed are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using compounds that ... 05/03/07 - 20070098713 - Nanoparticle delivery systems and methods of use thereof Certain embodiments of the invention relate to the use of small particles in biological systems, including the delivery of biologically active agents. Some embodiments involve using a collection of particles comprising an agent, a surfactant molecule having an HLB value of less than about 6.0 units, and a polymer soluble ... 05/03/07 - 20070098712 - method for making multispecific antibodies having heteromultimeric and common components The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method provides a multispecific antibody having a common light chain associated with each heteromeric polypeptide having an antibody ... 05/03/07 - 20070098711 - Methods of producing stable b-lymphocytes The invention provides a method of producing a stable lymphocyte culture and methods of producing monoclonal antibodies. ... 04/26/07 - 20070092507 - Anti-fcrn antibodies for treatment of auto/allo immune conditions Antibodies to heavy chain of human FcRn are provided which function as non-competitive inhibitors of IgG binding to FcRn. The antibodies may be polyclonal, monoclonal, chimeric or humanized, or antigen binding fragments thereof. These antibodies are useful for reducing the concentration of pathogenic IgGs in individuals and therefore used as ... 04/26/07 - 20070092506 - Use of rapamycin and agents that inhibit b7 activity in immunomodulation The invention provides methods for downmodulating an immune response comprising contacting immune cells from a subject with at least one agent that binds to at least one B7 molecule in combination with a Rapamycin compound. ... 04/26/07 - 20070092505 - Production of humanized antibodies in transgenic animals This invention relates to humanized antibodies and antibody preparations produced from transgenic non-human animals. The non-human animals are genetically engineered to contain one or more humanized immunoglobulin loci which are capable of undergoing gene rearrangement and gene conversion in the transgenic non-human animals to produce diversified humanized immunoglobulins. The present ... 04/26/07 - 20070092504 - Use of agents that modulate the interaction between pd-1 and its ligands in the downmodulation of immune responses Disclosed are methods for downmodulating an immune response comprising contacting an immune cell with an agent that modulates the interaction between PD-1 and a PD-1 ligand (e.g., soluble forms of PD-1 or PD-1 ligand or antibodies to PD-1) to thereby modulate the immune response. ... 04/12/07 - 20070081991 - Compositions and methods for modulation of immune responses The present invention relates to a novel mechanism for modulation of immune response. More closely, the present invention relates to modulation of CD94/NKG2 receptor yfunction by HLA-E+bound peptides causing either inhibition or absence of inhibition of said receptors. In a preferred embodiment the invention relates to HLA-E binding hsp (heat ... 04/12/07 - 20070081990 - Regulation of expression of high-affinity immunoglobulin e (ige) receptor beta-chain The present invention provides a polynucleotide comprising all or a part of the nucleotide sequence identified as SEQ ID NO:1 that regulates transcription of the human high-affinity IgE receptor (FcεRl) β-chain gene, and a method for regulating transcription of the FcεRl β-chain gene which comprises the step of promoting binding ... 04/05/07 - 20070077242 - Anti-cd40 monoclonal antibody An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40. ... 04/05/07 - 20070077241 - Activation of lymphocyte populations expressing nkg2d using anti-nkg2d antibodies and ligand derivatives The present invention provides various methods for stimulating a cell expressing an NKG2D receptor, including artificially engineered cell populations. Provided, in accordance with the invention, are monoclonal antibodies that bind to NKG2D extracellular domains and facilitate the interaction of other NKG2D domains with DAP10. Of particular interest are treating cancers ... 04/05/07 - 20070077240 - Immunoglobulins devoid of light chains The invention relates to an immunoglobulin having determined antigen specificity, and having a variable fragment which is derived from a so-called heavy-chain immunoglobulin having two heavy polypeptide chains capable of recognizing and binding one or several antigens and which is further naturally devoid of light chains, wherein the immunoglobulin having ... 03/29/07 - 20070071746 - C/clp antagonists and methods of use thereof The invention relates to the novel discovery that antagonizing a C/CLP can be useful for the treatment of diseases associated with the upregulation of one or more C/CLP such as Th2-driven and/or IL-13 mediated inflammatory diseases. Accordingly the present invention provides C/CLP antagonists and also provides compositions and methods for ... 03/29/07 - 20070071745 - Modified antigen binding molecules with altered cell signaling activity The present invention relates to modified antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies or fragments, including chimeric, primatized or humanized antibodies or fragments, having altered ability to mediate cell signaling activity by a target antigen, and/or altered ability to mediate cross-linking of ... 03/29/07 - 20070071744 - Agents which bind to epitopes of glycoprotein vi The present invention provides anti-thrombotic agents, methods for screening for said anti-thrombotics agents and methods of treating thrombotic and other cardiovascular disorders. ... 03/22/07 - 20070065428 - Early b-cell detection for selecting vaccines The present invention discloses an affinity-binding assay comprising a particle having at least four copies of a target molecule and at least two binding molecules specific for the target molecule, wherein a first of the binding molecules is associated with a first label and a second of the binding molecules ... 03/22/07 - 20070065427 - Agents that modulate immune cell activation and methods of use thereof Disclosed are methods for identifying an agent that modulates an immune response. One such method comprises screening for agents which inhibit the interaction between a PD-1 ligand and a PD-1 polypeptide, and determining whether the agents inhibit the interaction between a PD-1 ligand and a B7 polypeptide, to identify an ... 03/22/07 - 20070065426 - Tumor necrosis factor binding ligands The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of ... 03/15/07 - 20070059303 - Compositions and methods for the diagnosis and treatment of immune disorders The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. In particular, the invention describes a gene known in the art, alternatively, as ST2, T1 and Fit-1, and referred to herein as the 103 gene. The 103 gene is ... 03/15/07 - 20070059302 - Anti-vegf antibodies Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo. ... 03/15/07 - 20070059301 - Modified antibody fragments The present invention provides an antibody Fab or Fab′ fragment to which at least one effector molecule is attached characterized in that the heavy chain in the fragment is not covalently bonded to the light chain and both the interchain cysteine of CL and the interchain cysteine of CH1 have ... 03/08/07 - 20070053901 - Optimized fc variants and methods for their generation The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. ... 03/01/07 - 20070048300 - Antibodies having altered effector function and methods for making the same The invention provides a method of producing aglycosylated Fc-containing polypeptides, such as antibodies, having desired effector function. The invention also provides aglycosylated antibodies produced according to the method as well as methods of using such antibodies as therapeutics. ... 03/01/07 - 20070048299 - Methods of inducing an immune response Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene ... 02/22/07 - 20070041968 - Methods of inducing an immune response Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene ... 02/22/07 - 20070041967 - Igg fc fragment for a drug carrier and method for the preparation thereof Disclosed is an IgG Fc fragment useful as a drug carrier. Also, the present invention discloses a recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment, comprising culturing the transformant. When conjugated to a certain drug, ... 02/01/07 - 20070025985 - Immunoglobulins devoid of light chains There is provided an isolated immunoglobulin comprising two heavy polypeptide chains sufficient for the formation of a complete antigen binding site or several antigen binding sites, wherein the immunoglobulin is further devoid of light polypeptide chains. ... 02/01/07 - 20070025984 - Treatment of ulcerative colitis with tropomyosin isoforms and monoclonal antibodies to tropomyosin isoforms This invention pertains to a method for treating ulcerative colitis. Specifically, the method comprises orally or rectally administering to a human having ulcerative colitis a therapeutically effective amount of an antibody which binds to a tropomyosin isoform associated with ulcerative colitis. In another embodiment, the invention pertains to a method ... 01/25/07 - 20070020260 - Glycoprotein compositions The present invention concerns compositions comprising a glycoprotein having an Fc region, wherein about 80-100% of the glycoprotein in the composition comprises a mature core carbohydrate structure which lacks fucose, attached to the Fc region of the glycoprotein. The preferred glycoprotein is an antibody or immunoadhesin. ... 01/25/07 - 20070020259 - Anti-cd20 antibodies and fusion proteins thereof and methods of use The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD 20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases, and methods of treatment ... 01/25/07 - 20070020258 - Immunoglobulin variants The present invention describes IgE antagonists (including variant anti-IgE antibodies) and their use in diagnosis, therapy or prophylaxis of allergic and other IgE-mediated disorders, including asthma, food allergies, hypersensitivity and anaphylactic reactions. ... 01/25/07 - 20070020257 - Polypeptide The present invention provides a polypeptide inducing the production of an antibody in permucosal administration in the presence of no immunological adjuvant, a composition containing the polypeptide, and use thereof. The present invention solves the above object by providing a polypeptide inserted with a cell attachment motif of a cell ... 01/18/07 - 20070014789 - Humanized antibody conjugates and related methods, assays, reagents, and kits The invention provides synthetically and recombinantly-derived humanized antibody conjugates and related methods, diagnostic assays, reagents, and kits. In one embodiment, the invention provides humanized antibody conjugates comprising a human immunoglobulin fragment which is bound by a cross-linking functional group to a non-human antibody fragment (e.g., a non-human monoclonal antibody fragment) ... 01/18/07 - 20070014788 - Laminin-5 modulators and uses thereof Described herein are methods of treating or preventing various diseases and disorders using modulators of laminin-5. Exemplary diseases and disorders are inflammatory bowel disease, including ulcerative colitis and Crohn's disease, as well as polycystic kidney disease and cancers associated with one or more of the aforementioned conditions. Exemplary laminin-5 modulators ... 01/18/07 - 20070014787 - 71 human secreted proteins The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing ... 01/18/07 - 20070014786 - Methods for treating taxol-induced gut disorder This invention relates to the field of taxol-induced gut disorder. More specifically, the invention relates to methods of treating taxol-induced gut disorder comprising administration of agonist anti-trkC antibody for the treatment, prevention, and/or amelioration of a symptom of taxol-induced gut disorder. ... 01/11/07 - 20070009512 - Recombinant bivalent monospecific immunoglobulin having at least two variable fragments of heavy chains of an immunoglobulin devoid of light chains The present invention relates to fragments, especially variable fragments of immunoglobulins which are by nature devoid of light chains, these fragments being nevertheless capable of exhibiting a recognition and binding activity toward specific antigens. The present invention further relates to the use of such immunoglobulin fragments formed of at least ... 01/11/07 - 20070009511 - Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules The present invention provides use of soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig in the treatment of immune disorders associated with graft transplantation. ... 01/11/07 - 20070009510 - Monoclonal antibodies against ricin toxin and methods of making and using thereof Disclosed herein are monoclonal antibodies (Mabs) against ricin toxin and its subunits. The Mabs were initially selected based upon their ability to bind to ricin and its individual subunits in a solid-phase enzyme-linked immunoassay (ELISA). Several candidates were selected for further evaluation, including their ability to inhibit ricin intoxication in ... 01/11/07 - 20070009509 - Antibody against nox1 polypeptide, method of diagnosing cancer with the use of nox1 gene and method of screening cancer growth inhibitor The present invention provides a diagnostic method for cancer, a screening method for a cancer growth inhibitor, and a pharmaceutical composition used in cancer therapy using a Nox1 gene associated with a mutant Ras oncogene. More specifically, the present invention relates to: a composition for producing an antibody, comprising a ... 01/11/07 - 20070009508 - Methods for obtaining antibodies The invention is directed towards a method of enriching a population of cells in those cells that produce an antibody which recognises an antigen of interest. In particular, an untagged antigen is used in conjunction with a polyclonal antibody to isolate cells recognizing said antigen. ... 01/04/07 - 20070003546 - Optimized fc variants and methods for their generation The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. ... 01/04/07 - 20070003545 - Interleukin-8 homologous polypeptides and therapeutic uses thereof The present invention is directed to novel polypeptides having structural homology to IL-8 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies ... 12/28/06 - 20060292139 - Fusion proteins for prodrug activation The invention relates to compounds which contain an antigen binding region which is bound to at least one enzyme which is able to metabolize a compound (prodrug) which has little or no cytotoxicity to a cytotoxic compound (drug), where the antigen binding region is composed of a single polypeptide chain. ... 12/21/06 - 20060286099 - Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of ... 12/21/06 - 20060286098 - Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of ... 12/21/06 - 20060286097 - Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of ... 12/21/06 - 20060286096 - Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of ... 12/21/06 - 20060286095 - Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of ... 12/21/06 - 20060286094 - Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of ... 12/21/06 - 20060286093 - Soluble receptor br43x2 and methods of using Soluble, secreted tumor necrosis factor receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise one cysteine-rich repeat that is homologous to other tumor necrosis factor receptors, such as transmembrane activator and CAML-interactor (TACI). The polypeptides may be used for detecting ligands, agonists and ... 12/21/06 - 20060286092 - Methods of using pnkp30, a member of the b7 family, to modulate the immune system Novel methods of using isolated polypeptides, isolated polynucleotides encoding the polypeptides, and related compositions are disclosed for pNKp30 protein. The methods involved modulating the proliferation of T-cells in vitro and in vivo and modulation of immune response. The present invention also includes methods for producing pNKp30, including soluble molecules, uses ... 12/21/06 - 20060286091 - Rela-associated inhibitor, process for producing the same and utilization thereof Human RelA-associated inhibitor (RAI) comprising 351 amino acid, process for producing it, cDNA encoding it, fragment capable of hybridizing selectively to the cDNA sequence, plasmid for expression and duplication comprising the cDNA, host cell transformed with the plasmid, antibody against the polypeptide, pharmaceutical composition comprising the polypeptide or the antibody ... 12/14/06 - 20060280736 - Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of ... 12/14/06 - 20060280735 - Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of ... 12/14/06 - 20060280734 - Retargeting The present invention relates to a method for the generation of immunoglobulin molecules of predetermined specificity. In particular, the invention relates to a method for the retargeting of the epitope binding specificity of one or more antibodies using single variable domains which exhibit a dominant epitope binding specificity. ... 12/14/06 - 20060280733 - Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence Compositions of matter that comprise one or more conformational epitopes found on amyloid peptide aggregates, antibodies to such epitopes and methods for making and using the compositions, eptitopes and/or antibodies. The invention includes synthetic or isolated compositions that contain or consist of certain conformational epitopes that are found on peptide ... 12/07/06 - 20060275286 - Antibody and use of the same The present invention aims at providing an antibody, by which metastin or its derivative can be quantified specifically with a high sensitivity, a method of detecting/quantifying metastin or its derivative using the antibody, and a diagnostic agent (e.g., a diagnostic for pregnancy) the same. Specifically, an antibody capable of specifically ... 12/07/06 - 20060275285 - Methods of inhibiting a gpcr The invention provides methods of identifying modulators, for example, inhibitors, of a G-protein coupled receptor. The modulators can be used for the treatment or prevention of metabolic disorders such as dyslipidemia, metabolic syndrome and obesity. The invention also provides methods of treating or preventing metabolic disorders by administering modulators of ... 11/30/06 - 20060269544 - Polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, bgs42 The present invention provides novel polynucleotides encoding BGS-42 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-42 polypeptides to the diagnosis, treatment, and/or prevention ... 11/30/06 - 20060269543 - Compositions and methods for increasing the stability of antibodies The invention encompasses pharmaceutical compositions comprising an antibody and methods of formulating antibodies. The heavy and/or a light chain variable region of the antibody may have certain characteristics. In some embodiments, the antibody may comprise an N-glycan site in a heavy and/or light chain variable region. The compositions may comprise ... 11/30/06 - 20060269542 - Immunoliposome composition for targeting to a her2 cell receptor An immunoliposome composition comprised of liposomes bearing a ligand for targeting to cells expressing a growth factor receptor, such as HER2, is described. Binding of the immunoliposome to HER2-expressing cells results in internalization of the immunoliposome for cytoplasmic delivery of an entrapped drug. ... 11/30/06 - 20060269541 - S.agalactiae antigens i + ii The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. agalactiae, methods for isolating such antigens and specific uses thereof. ... 11/30/06 - 20060269540 - Targeted cd1d molecules The invention is directed to a compound comprising one or more CD1d complexes in association with an antibody specific for a cell surface marker. The CD1d complexes comprise a CD1d, a β2-microglobulin molecule, and may further comprise an antigen bound to the CD1d binding groove. The invention is further directed ... 11/23/06 - 20060263354 - Antibodies to myostatin The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to myostatin, and that function to inhibit myostatin. The invention also relates to human anti-myostatin antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or ... 11/23/06 - 20060263353 - Methods for obtaining antibodies The invention is directed towards a method of enriching a population of cells in those cells that produce an antibody which recognises an antigen of interest. In particular, an untagged antigen is used in conjunction with a polyclonal antibody to isolate cells recognizing said antigen. ... 11/23/06 - 20060263352 - Quantification of botulinum toxin The invention relates to a method for determining the quantity of pre-synaptic neuromuscular blocking substance (notably botulinum toxin) contained in a sample. In one aspects, the method comprises the following steps: (i) determining the minimum voltage Vm needed to induce the contraction of muscle tissue, said muscle tissue being connected ... 11/23/06 - 20060263351 - Methods and compositions for protection against thrombolysis associated reperfusion injury The invention relates to products and methods for reducing cerebral hemorrhage and edema, which can be negative side-effects of thrombolytic therapies with tissue plasminogen activator (tPA) and/or urokinase plasminogen activator (uPA). ... 11/16/06 - 20060257395 - System and method for magnifying a humoral immune response The present application relates, in general, to a system and/or method for detection and/or treatment. ... 11/16/06 - 20060257394 - Modified antibody fab fragments The present invention provides antibody Fab fragments in which the heavy chain constant region terminates at the interchain cysteine of CH1. Also provided are antibody Fab fragments in which the heavy chain constant region terminates at the interchain cysteine of CH1 to which one or more effector molecules are attached. ... 11/02/06 - 20060246059 - Pharmaceutically acceptable fn3 polypeptides for human treatments Disclosed herein are proteins that include an immunoglobulin fold and that can be used as scaffolds. Also disclosed herein are nucleic acids encoding such proteins and the use of such proteins in diagnostic methods and in methods for evolving novel compound-binding species and their ligands. ... 11/02/06 - 20060246058 - Single-domain antigen-binding antibody fragments derived from llama antibodies A phage display library of variable heavy domain (VHH or VH) fragments (sdAb fragments) derived from the antibody repertoire of a non-immunized llama is disclosed. The sdAb fragments of the library are characterized by the absence of cysteine residues in complementarity determining regions (CDRs) and a very low presence of ... 11/02/06 - 20060246057 - Treatment or prevention of damage due to radiation exposure A method of treatment or prevention of damage due to ionizing radiation exposure involves administering to a subject in need of such treatment an effective amount of a composition containing 1) a compound including a radiation damage-inhibiting polypeptide containing amino acid sequence LKKTET (such as Thymosin β4), a conservative variant ... 10/26/06 - 20060240001 - P-cadherin antibodies The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to P-cadherin, and that function to inhibit P-cadherin. The invention also relates to heavy and light chain immunoglobulins derived from human P-cadherin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates ... 10/19/06 - 20060233789 - Process for producing antigenic substance An object of the present invention is to provide a means for producing an antigenic component with the retained native antigenicity using a cell-free protein synthesis. In particular, it is an object to provide a means for producing an antigenic component without depending on codon usage, like expressing an antigenic ... 10/19/06 - 20060233788 - Anti-ghrelin antibodies Monoclonal antibodies, including humanized and chimeric antibodies, that bind acylated and unacylated human ghrelin are provided. Such monoclonal antibodies can be full-length, or an antigen-binding portion thereof, and are useful for neutralizing ghrelin activity, e.g., in a human subject suffering from a disorder in which ghrelin activity is detrimental. ... 10/12/06 - 20060228350 - Framework-shuffling of antibodies The present invention relates to methods of reengineering or reshaping antibodies to reduce the immunogenicity of the antibodies, while maintaining the immunospecificity of the antibodies for an antigen. In particular, the present invention provides methods of producing antibodies immunospecific for an antigen by synthesizing a combinatorial library comprising complementarity determining ... 10/12/06 - 20060228349 - Anti-addl antibodies and uses thereof The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also ... 09/28/06 - 20060216285 - Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies. ... 09/28/06 - 20060216284 - Macromolecules comprising a thioether cross-link The present invention provides macromolecules comprising at least one thioether cross-link. A thioether cross-link comprising a single thioether bond between two residues of a macromolecule. The macromolecules of the invention can display enhanced stability, pharmaceutical properties and functional properties. In particular, the invention provides an isolated antibodies comprising at least ... 09/28/06 - 20060216283 - Inhibition of secretion from non-neuronal cells A method of treatment of disease by inhibition of cellular secretory processes is provided. The method has particular application in the treatment of diseases dependent upon the exocytotic activity of endocrine cells, exocrine cells, inflammatory cells, cells of the immune system, cells of the cardiovascular system, and bone cells. Agents ... 09/28/06 - 20060216282 - Methods for inhibiting cutaneous inflammation and hyperpigmentation This invention provides a method of preventing or treating in a subject contact dermatitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat contact dermatitis so as to thereby prevent or treat contact dermatitis ... 09/21/06 - 20060210557 - Stabilized liquid polypeptide formulations The present invention provides formulations for maintaining the stability of polypeptides, in particular, therapeutic antigen-binding polypeptides such as antibodies and the like, for example, anti-Aβ antibodies. The formulations generally include an antioxidant in a sufficient amount as to inhibit by-product formation, for example, the formation of high molecular weight polypeptide ... 09/21/06 - 20060210556 - Novel composition and methods for the treatment of immune disorders The present invention relates to compositions of matter and methods for the treatment and diagnosis of immune related diseases, including those mediated by cytokines released primarily either Th1 or Th2 cells in response to antigenic stimulation. The present invention further relates to methods for biasing the differentiation of T-cells in ... 09/21/06 - 20060210555 - Compositions comprising immunoreactive reagents and saponins, and methods of use thereof The present invention relates to pharmaceutical compositions that are useful for the prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), neurodegenerative or amyloid diseases, or any other disease wherein the treatment of such disease would be improved by an enhanced immune response, and methods of ... 09/14/06 - 20060204494 - Methionine sulfoxide antibodies Antibodies specific for methionine sulfoxide residues on proteins are provided. The antibodies are prepared using methionine-rich zein proteins, which are oxidized, as antigens. ... 09/14/06 - 20060204493 - Heteromultimeric molecules The invention provides heteromultimeric antibodies, and methods of making these antibodies at high yields and purity. The invention also provides methods and compositions for using these antibodies. ... 09/07/06 - 20060198840 - Molecules with extended half-lives, compositions and uses thereof The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant ... 08/31/06 - 20060193852 - Novel cd19xcd3 specific polypeptides and uses thereof Described are novel single-chain multifunctional polypeptides comprising at least two binding sites specific for the CD19 and CD3 antigen, respectively. Further provided are polypeptides, wherein the above-described polypeptide comprises at least one further domain, preferably of pre-determined function. Furthermore, polynucleotides encoding said polypeptides as well as to vectors comprising said ... 08/31/06 - 20060193851 - Human anti-factor ix/ixa antibodies The invention provides for the isolation, identification, synthesis, expression and purification of antibodies reactive with factor IX (FIX)/factor IXa (IXa). In particular aspects, the invention provides human antibodies reactive with the human FIX Gla domain. The invention further provides compositions especially pharmaceutical compositions, articles of manufacture, and methods of inhibiting ... 08/31/06 - 20060193850 - Anti a beta antibody formulation The present invention provides formulations for maintaining the stability of Aβ binding polypeptides, for example, Aβ antibodies. Exemplary formulations include a tonicity agent such as mannitol and a buffering agent or amino acid such as histidine. Other exemplary formulations include an antioxidant in a sufficient amount as to inhibit by-product ... 08/31/06 - 20060193849 - Biological materials and uses thereof A modified antibody molecule which selectively binds to a specific target, the antibody molecule being modified at at least one amino acid residue that determines antigen binding selectivity and/or affinity, characterised in that the modified antibody molecule exhibits a greater stability than an unmodified parent antibody molecule which selectively binds ... 08/31/06 - 20060193848 - Mammalian tumor susceptibility genes and their uses TSG101 is a tumor susceptibility gene whose homozygous functional knock out in fibroblasts leads to transformation and the ability of these cells to form metastatic tumors in nude mice. The cellular transformation that results from inactivation of TSG101 is reversible by restoration of TSG101 function. Decreased expression of TSG101 is ... 08/24/06 - 20060188497 - Immunotherapeutic combination for the treatment of tumors that over-express receptors with tyrosine kinase activity The present invention is related to the field of immunology and more specifically to cancer immunotherapy, particularly with immunotherapeutic combinations and treatment methods to prevent tumor cell growth and/or to eliminate those cells. The methods described in the present invention are based on the blockade of receptors with protein kinase ... 08/24/06 - 20060188496 - Intranasal administration of active agents to the central nervous system A method for delivering a polypeptide to the central nervous system of a mammal is provided. The method involves attaching the polypeptide to an antibody or an antibody fragment and administering the fusion polypeptide intranasally, for delivery to the central nervous system. Methods of treatment are also provided, where a ... 08/24/06 - 20060188495 - Treatment method The invention provides methods of treating autoimmune diseases using lower doses of anti-CD20 antibodies effective to deplete B cells in the patient. ... 08/24/06 - 20060188494 - Method for treating established spontaneous auto-immune diseases in mammals A method of treating spontaneous and ongoing auto-immune diseases in mammals, comprising administering to a mammal, in need of such a treatment, a therapeutically effective amount of one or more non mitogenic anti-CD3 active principles to achieve permanent disease remission through the induction of antigen-specific unresponsiveness, i.e. immune tolerance. ... 08/24/06 - 20060188493 - Use of an active substance that binds to cd28 for producing a pharmaceutical composition The invention relates to the use of a CD28-specific superagonistic monoclonal antibody (mAb) or of a mimic compound of the same for producing a pharmaceutical composition for the induction and/or reproduction of regulatory T-cells. ... 08/17/06 - 20060182742 - System and method for magnifying a humoral immune response The present application relates, in general, to a system and/or method for detection and/or treatment. ... 08/17/06 - 20060182741 - Use of adcc-optimized antibodies for treating weak patients The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F ... 08/17/06 - 20060182740 - Buffered formulations for concentrating antibodies and methods of use thereof The present invention provides a method for producing a concentrated antibody preparation that includes the steps of: (a) obtaining an initial antibody preparation that is an aqueous solution of antibodies and histidine or acetate buffer at a concentration in the range of from about 2 mM to about 48 mM; ... 08/10/06 - 20060177437 - Binding peptides: methods for their generation and use Described are means and methods for generating binding peptide associated with a suitable core region, the resulting proteinaceous molecule and uses thereof. The invention provides a solution to the problems associated with the use of binding molecules over their entire range of use. Binding molecules can be designed to accommodate ... 08/10/06 - 20060177436 - Methods for treating autoimmune disorders The present invention relates to methods for treating autoimmune disorders. In an embodiment, the invention is directed to a method for treating an autoimmune disorder comprising administering a TCCR agonist. In an embodiment, the autoimmune disorder is at least partially mediated by a Th1 response. In an embodiment, the autoimmune ... 08/10/06 - 20060177435 - Methods for assessing atherogenesis by determining oxidized phospholipid to apolipoprotein b ratios The present invention relates to the analysis of oxidized phospholipids (OxPL) on apolipoprotein B-100 in patients at high risk or with documented coronary artery disease (CAD) or acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction or suspected of being at risk for ACS. Such methods are ... 08/03/06 - 20060171943 - Compositions and methods of treating fibrotic disorders The invention provides methods and compositions for reducing or preventing fibrosis in a subject suffering from a fibrotic disorder by administering a therapeutically effective amount of at least one antagonist to the cytokine thymic stromal lymphopoietin to the subject. In one embodiment, the methods and compositions further comprise administering at ... 08/03/06 - 20060171942 - Modified fusion molecules for treatment of allergic disease The present invention comprises a fusion molecule comprising a Fcε fragment sequence including functionally active CH2, CH3 and CH4 domains of the constant region of an IgE heavy chain (CHε2-CHε3-CHε4 sequence) linked at its C-terminus to the N-terminus of a second polypeptide including functionally active hinge, CH2 and CH3 domains ... 08/03/06 - 20060171941 - Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use Humanized anti-TAG-72 CC49 monoclonal antibodies are disclosed herein. The antibodies include a light chain Complementarity Determining Region (L-CDR)1, a L-CDR2, and a L-CDR3; and a heavy chain Complementarity Determining Region (H-CDR)1, a H-CDR2, and a H-CDR3 from humanized antibody HuCC49V10. The L-CDR1, L-CDR2, L-CDR3 are within a HuCC49V10 light chain ... 08/03/06 - 20060171940 - Antibody disulfide isomers, use thereof, and methods of analyzing same The present invention relates to disulfide isomers of an antibody having specificity for antigenic determinants of human tumor necrosis factor alpha (TNFα). The present invention also relates to compositions comprising the isomers and therapeutic uses of the antibody. The present invention also relates to analytical methods of detecting the TNFα ... 07/27/06 - 20060165681 - Antibodies Invented are non-peptide TPO mimetics. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative. ... 07/27/06 - 20060165680 - Humanized anti-tag 72 cc49 for diagnosis and therapy of human tumors The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the ... 07/27/06 - 20060165679 - Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 2 (vpac2) The invention provides a human VPAC2 which is associated with the disorders of the peripheral and central nervous system, cardiovascular diseases, hematological diseases, genitourinary diseases, inflammation. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and central nervous ... 07/20/06 - 20060159679 - Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants Lyophilized compositions of TFPI or a TFPI variant suitable for long-term storage can be formed by lyophilizing an aqueous formulation of the TFPI or TFPI variant having a pH from about 4 to about 8 with a carbohydrate or amino acid glass forming agent. These lyophilized compositions are stable for ... 07/20/06 - 20060159678 - Modulators of cytokine mediated signaling pathways and integrin alphabeta3 receptor antagonists for combination therapy The invention relates to the use of modulators of cytokine mediated signalling pathways in combination with integrin αvβ3 receptor antagonists for the treatment or prevention of diseases, particularly to the use of a pharmaceutical composition, comprising a modulator of cytokine mediated signalling pathways and an integrin αvβ3 receptor antagonist, for ... 07/20/06 - 20060159677 - Tumour necrosis factor peptide binding antibodies Provided are isolated antibodies or fragments thereof which bind a peptide consisting of residues Gly54-Leu55-Tyr56-Leu57-Ile58-Tyr59-Ser60-Gln61-Val62-Leu63-Phe64-Lys65-Gly66-Gln67-Gly68 (peptide 308) of mature human TNF-α. The antibodies and fragments thereof may be used to identify antibodies capable of binding in the region of mature human TNF-α of amino acid resides 54-68. Antibodies or fragments ... 07/20/06 - 20060159676 - Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions Novel methods of inhibiting angiogenesis, lymphangiogenesis, tumorigenesis, inflammation, or metastasis, or promoting apoptosis with compositions that inhibit the apelin/APJ signaling pathway are provided. Also provided are methods of promoting angiogenesis or lymphangiogenesis, or inhibiting apoptosis with compositions comprising an apelin polypeptide or small molecule agonist. The present invention further provides ... 07/20/06 - 20060159675 - Compositions and methods for treating coagulation related disorders Disclosed are methods for preventing or treating sepsis, a sepsis-related condition or an inflammatory disease in a mammal. In one embodiment, the method includes administering to the mammal a therapeutically effective amount of at least one humanized antibody, chimeric antibody, or fragment thereof that binds specifically to tissue factor (TF) ... 07/20/06 - 20060159674 - Signaling intermediates in an in vitro model of alzheimer's disease The invention provides a novel human protein, FISH adaptor protein, involved in amyloid β-protein-mediated cell death. Also provided are methods for modulating amyloid β-protein-mediated cell death using agents that interfere with the activity of FISH adaptor protein. ... 07/20/06 - 20060159673 - Methods of screening light chain of antibody The present invention relates to methods of screening for commonly shared light chains, in which the method comprises the steps of (a) generating a host secreting the heavy chain of an antibody that binds to a desired antigen; (b) introducing an antibody light chain library into the host of step ... 07/13/06 - 20060153838 - Fc region variants The present invention provides polypeptide Fc region variants and oligonucleotides encoding Fc region variants. Specifically, the present invention provided compositions comprising novel Fc region variants, methods for identifying useful Fc region variants, and methods for employing Fc region variants for treating disease. ... 07/13/06 - 20060153837 - Treating autoimmune diseases with humanized anti-cd401 antibodies The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases; and an immunosuppressant during transplantation of heterologous cells, tissues or organs, cell therapy, and gene therapy. ... 07/13/06 - 20060153836 - Molecules and methods for inhibiting shedding of kim-1 Disclosed are antibodies that inhibit proteolytic release of a soluble KIM-1 polypeptide from KIM-1 expressing cells. Also disclosed are methods of using the antibodies to inhibit shedding of the KIM-1 polypeptide. ... 07/13/06 - 20060153835 - Treatment of pre-eclampsia in pregnant women using targeted apheresis This invention uses “targeted apheresis” to treat pregnant women who are at risk of developing eclampsia. “Targeted Apheresis” is a process whereby the sFlt-1 receptors responsible for causing the disease symptoms are selectively removed from the blood by passing the blood through a cartridge containing either immobilized PIGF, and/or through ... 07/13/06 - 20060153834 - Purification of immunoglobulins using affinity chromatography and peptide ligands An immunoglobulin binding peptide having the general formula, from amino terminus to carboxy terminus, of Z-R1—R2—R3—R4—R5—R6—X, is described, wherein: R1 is H or Y; R2 is a hydrophobic, preferentially aromatic, amino acid (for example W, F, Y, V); R3 is a positively charged or aromatic amino acid (for example R, ... 07/13/06 - 20060153833 - Anti hepatitis c virus antibody and uses thereof Described are novel antibodies specifically recognizing conformation dependent epitopes of HCV glycoprotein E2 and that are capable aof neutralizing the binding of E2 protein onto susceptible cells. Furthermore, antigens and epitopes recognized by the above-described antibodies as well as polynucleotides encoding said antibodies are provided. Also provided are to vectors ... 07/06/06 - 20060147446 - Humanized antibodies to human gp39, compositions, and therapeutic uses thereof The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases. ... 07/06/06 - 20060147445 - Immunoglobulin dna cassette molecules, monobody constructs, methods of production, and methods of use therefor Featured are DNA molecules, expression vectors, and host cells useful for creation of immunoglobulins, as well as novel immunoglobulin molecules termed monobodies. Additionally provided are methods of production of immunoglobulins, including monobodies, as well as methods of using the disclosed immunoglobulin and monobody constructs, expression vectors and host cells containing ... 07/06/06 - 20060147444 - Biosynthetic binding proteins for immuno-targeting Disclosed is a formulation for targeting an epitope on an antigen expressed in a mammal. The formulation comprises a pharmaceutically acceptable carrier together with a dimeric biosynthetic construct for binding at least one preselected antigen. The biosynthetic construct contains two polypeptide chains, each of which define single-chain Fv (sFv) binding ... 06/29/06 - 20060140937 - B7-related nucleic acids and polypeptides useful for immunomodulation The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated ... 06/29/06 - 20060140936 - Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer Methods and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases, using multispecific antagonists that target at least two different markers are disclosed. The different targets include (i) proinflammatory effectors of the innate immune system, (ii) coagulation factors, and (iii) targets specifically associated with an inflammatory or immune-dysregulatory disorder, with a ... 06/29/06 - 20060140935 - Platlet glycoprotein ib alpha fusion polypeptides and methods of use thereof The present invention provides compositions and methods for treating or preventing vascular-associated disorders. ... 06/29/06 - 20060140934 - Modified fc molecules The present invention concerns molecules and a process in which one or more biologically active peptides are incorporated into an Fc domain. In this invention, pharmacologically active compounds may be prepared by a process comprising (a) selecting at least one peptide that modulates the activity of a protein of interest; ... 06/29/06 - 20060140933 - Compositions and methods for treating rage-associated disorders Fusion proteins comprising a Receptor for Advanced Glycation End Products Ligand Binding Element (RAGE-LBE) and an immunoglobulin element are disclosed. Also disclosed are fusion proteins comprising a RAGE-LBE and a dimerization domain. Also disclosed are nucleic acids encoding such fusion proteins and methods for using disclosed nucleic acids and proteins ... 06/29/06 - 20060140932 - Human il-1 beta antagonists The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind mature human IL-1 Beta. These antibodies, or antigen-binding portions thereof, generally exhibit high binding affinities (low kooff values), reduced deamidation compared to the native antibody, and can be used to treat various diseases such as rheumatoid arthritis, ... 06/29/06 - 20060140931 - Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment The invention provides a bispecific molecule comprising an antibody that binds a C3b-like to one or more antigen-binding antibody fragments, each of which binds an antigenic molecule. The invention also provides methods of producing such bispecific molecules and to therapeutic uses of such bispecific molecules. The invention further provides bispecific ... 06/22/06 - 20060134107 - Immunoglobulins devoid of light chains The invention relates to an immunoglobulin having determined antigen specificity, and having a variable fragment which is derived from a so-called heavy-chain immunoglobulin having two heavy polypeptide chains capable of recognizing and binding one or several antigens and which is further naturally devoid of light chains, wherein the immunoglobulin having ... 06/22/06 - 20060134106 - Antibody composition and passive immunization against pregnancy-induced hypertension A composition is provided to prevent, limit the effects of, delay the onset of, or treat one or more of the causes, symptoms or complications of gestational hypertension, preeclampsia, eclampsia and/or intrauterine growth restriction. The composition comprises a therapeutically effective amount of an antibody that reacts immunologically with or binds ... 06/22/06 - 20060134105 - Igg immunoglobulin variants with optimized effector function The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes. ... 06/22/06 - 20060134104 - Humanized anti-cmet antagonists The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies. ... 06/22/06 - 20060134103 - Compounds and molecular complexes comprising multiple binding regions directed to transcytotic ligands Disclosed herein are multimeric molecular complexes and compounds that are multivalent, i.e., they have two or more targeting elements directed to a ligand that confers paracellular transporting properties and/or transcytotic properties to complexes and compounds to which it is bound. The complexes and compounds have properties that are different from ... 06/22/06 - 20060134102 - Lymphotoxin beta receptor agents in combination with chemotherapeutic agents This invention features combination therapies that include a composition that activates lymphotoxin-beta receptor signaling in combination with one or more other chemotherapeutic agents, as well as therapeutic methods and screening methods for identifying agents that in combination with a lymphotoxin-beta receptor agonist agent have a supra-additive effect on tumor inhibition. ... 06/22/06 - 20060134101 - Use of avian antibodies The present invention relates to a novel method for treatment and prophylaxis of infections, especially enteric infections, in newborns, which is both safe and effective. This is achieved by using IgY directed against microbes, in particular against Enterobacter cloacae, which have been obtained by hyperimmunising birds with an antigen (microbe) ... 06/22/06 - 20060134100 - Dc-sign blockers and their use for preventing or treating viral infections The present invention relates to methods and compositions for preventing or treating diseases of a mammal, including viral infections, wherein at least one symptom of the disease is mediated at least in part by the binding of an effector molecule to a DC-SIGN receptor present on cells of the mammal ... 06/15/06 - 20060127395 - Stable liquid formulations of antibodies The present invention provides stable liquid formulations of antibodies suitable for parenteral administration. Also, provided are aqueous solutions which have high concentrations of therapeutical antibodies which may be used to produce therapeutical liquid formulations. The present invention also relates to uses, such as medical uses, of the stable liquid formulations ... 06/15/06 - 20060127394 - Cloning of honey bee allergen The present invention relates to a nucleic acid encoding a polypeptide capable of binding to IgE from subjects allergic to venom of an insect from the order Hymenoptera having a homology of more than 70% to the amino acid sequence of SEQ ID NO: 2, which is the honey bee ... 06/15/06 - 20060127393 - Antibodies to dkk-1 The present invention provides antibodies and immunologically functional fragments thereof that specifically bind Dkk-1 polypeptides. The subject antibodies and fragments bind with high affinity to a conformational epitope located in the carboxy region of the Dkk-1 protein. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable ... 06/15/06 - 20060127392 - Antibody for adcc and inducing cytokine production The invention concerns chimeric monoclonal antibodies, humanized or human produced in selected cell lines, said antibodies exhibiting high affinity for the CD16 receptor of effector cells of the immune system and hence capable of inducing high ADCC, but also the property of inducing cytokine and interleukin secretion, in particular IFNγ, ... 06/15/06 - 20060127391 - Methods and materials for treating inflammatory conditions Methods and kits for treating inflammatory conditions are described that include modulating kallikrein 6 protease activity. ... 06/08/06 - 20060121026 - Immunoglobulins devoid of light chains The invention relates to an immunoglobulin having determined antigen specificity, and having a variable fragment which is derived from a so-called heavy-chain immunoglobulin having two heavy polypeptide chains capable of recognizing and binding one or several antigens and which is further naturally devoid of light chains, wherein the immunoglobulin having ... 06/08/06 - 20060121025 - Vegf-related protein A human VEGF-related protein (VRP) has been identified and isolated that binds to, and stimulates the phosphorylation of, the receptor tyrosine kinase Flt4. The VRP is postulated to be a third member of the VEGF protein family. Also provided are antibodies that bind to VRP and neutralize a biological activity ... 06/08/06 - 20060121024 - Novel class of sterol ligands and their uses in regulation of cholesterol and gene expression This invention relates to oxysteroids and oxysteroid hormones which have been identified. These oxysteroids are C27 modified sterols, particularly derivatives of intermediates in cholesterol synthesis, including lanosterol, zymosterol and desmosterol, including C27 diol and C27 acid derivatives, as well as related compounds and analogs thereof. The oxysteroids are capable of ... 06/08/06 - 20060121023 - Method to decrease nonspecific staining by cy5 Methods of reducing nonspecific binding of a fluorophore to cells expressing a Fc receptor, for example, CD64, is provided. ... 06/08/06 - 20060121022 - Apc non-neutralizing anti-body The present invention provides anti-aPC antibodies that suppress the inactivation of activated protein C (aPC), and uses thereof. The present inventors screened anti-aPC antibodies, and succeeded in isolating anti-aPC antibodies comprising the activity of suppressing aPC inactivation in blood. The antibodies of the present invention can be used to maintain ... 06/08/06 - 20060121021 - Microparticle with cd28-specific monoclonal antibodies The invention relates to microparticles with a support structure and CD28-specific superagonistic monoclonal antibodies (mAbs) bonded to the support structure or a compound mimicking the above. ... 06/01/06 - 20060115474 - Ligands for use in therapeutic compositions for the treatment of hemostasis disorders The invention, in general, features a method of treatment and/or prevention of a thrombotic pathological condition, in a mammal, which includes administering to the mammal in need of such treatment a therapeutically effective amount of a composition including an antibody directed against the C1 domain of Factor VIII, which is ... 06/01/06 - 20060115473 - Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists Methods of, and compositions for, treating central nervous system injury with an antagonist of an alpha4 subunit containing integrin are described. ... 06/01/06 - 20060115472 - Stabilizing formulations Formulations are described that are suitable for storage of proteins, such as antibodies, over a relatively broad range of protein concentrations, pH, and buffer types. Also described are methods of storing a protein and methods of identifying a suitable formulation for storage of a specific protein. In general, a formulation ... 05/25/06 - 20060110383 - Immunopotentiative composition Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods ... 05/25/06 - 20060110382 - Antibody peg positional isomers, compositions comprising same, and use thereof The present invention relates to recombinant protein PEG positional isomers. More specifically, it relates to PEG positional isomers of an antibody having specificity for antigenic determinants of human tumor necrosis factor alpha (TNFα). More specifically, it relates to PEG positional isomers of CDP870. The present invention also relates to compositions ... 05/11/06 - 20060099209 - Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases The invention concerns novel DNA and amino acid sequences of monoclonal antibodies. (mAbs) raised against lymphoblastoid cells and peptides to which the mAbs bind to. The invention also concerns diagnostic assays using said antibodies or peptides for detecting individuals with a high probability of having a malignant disease and, at ... 05/11/06 - 20060099208 - Method of potentiating the therapeutic action of monoclonal and polyclonal antibodies A method of potentiating the action of monoclonal/polyclonal antibodies against growth factors and their receptors by coupled conjugation with EFAs/PUFAs (optionally with a lymphographic agent) in the prevention and/or treatment of cancer, and inflammatory conditions such as rheumatoid arthritis, systemic lupus erythematosus, progressive systemic sclerosis, mixed connective tissue disorder, vasculitis. ... 05/11/06 - 20060099207 - High affinity antibodies against hmgb1 and methods of use thereof Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present ... 05/11/06 - 20060099206 - Methods and compositions for improving recombinant protein production Nucleic acid molecules modified to enhance recombinant protein, e.g., antibody, expression and/or reduce or eliminate mis-spliced and/or intron read-through (IRT) by-products are disclosed. The invention also provides methods for producing proteins devoid of mis-spliced and/or intron read-through by-products by the use of such vectors in host cells under cell culture ... 05/11/06 - 20060099205 - Bispecific single chain fv antibody molecules and methods of use thereof Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family. ... 05/11/06 - 20060099204 - Methods for antibody engineering The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying |